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Rueda JO, Palomeque J, Mattiazzi A. Early apoptosis in different
models of cardiac hypertrophy induced by high renin-angiotensin system
activity involves CaMKII. J Appl Physiol 112: 2110–2120, 2012. First
published April 5, 2012; doi:10.1152/japplphysiol.01383.2011.—The
objective of this study was to establish whether 1) hyperactivity of
renin-angiotensin-aldosterone system (RAAS) produces apoptosis in
early stages of cardiac disease; and 2) Ca21-calmodulin-dependent
protein kinase II (CaMKII) is involved in these apoptotic events. Two
models of hypertrophy were used at an early stage of cardiac disease:
spontaneously hypertensive rats (SHR) and isoproterenol-treated rats
(Iso-rats). At 4 mo, SHR showed blood pressure, aldosterone serum
levels, used as RAAS activity index, and left ventricular mass index,
used as hypertrophy index, above control values by 84.2 6 2.6
mmHg, 211.2 6 25.8%, and 8.6 6 1.1 mg/mm, respectively. There
was also an increase in apoptotis (Bax-to-Bcl-2 ratio and terminal
deoxynucleotidyl transferase dUTP-mediated nick-end labeling posi-
tive cells) associated with an enhancement of CaMKII activity with
respect to age-matched controls (phosphorylated-CaMKII, 98.7 6
14.1 above control). Similar results were observed in 4-mo-old Iso-
rats. Cardiac function studied by echocardiography remained unal-
tered in all groups. Enalapril treatment significantly prevented hyper-
trophy, apoptosis, and CaMKII activity. Moreover, intracellular Ca21
handling in isolated myocytes was similar between SHR, Iso-rats, and
their aged-matched controls. However, SHR and Iso-rats showed a
significant increase in superoxide anion generation (lucigenin) and
lipid peroxidation (thiobarbituric acid reactive substance). In trans-
genic mice with targeted cardiomyocyte expression of a CaMKII
inhibitory peptide (AC3-I) or a scrambled control peptide (AC3-C),
Iso treatment increased thiobarbituric acid reactive substance in both
strains, whereas it increased CaMKII activity and apoptosis only in
AC3-C mice. Endogenous increases in RAAS activity induce ROS
and CaMKII-dependent apoptosis in vivo. CaMKII activation could
not be associated with intracellular Ca21 increments and was directly
related to the increase in oxidative stress.
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EXPERIMENTAL EVIDENCE INDICATES that a critical factor in the
transition from compensated to noncompensated cardiac hy-
pertrophy is myocyte cell loss by apoptosis and necrosis (42).
The circulating levels of angiotensin II (ANG II) are increased
in heart failure and may constitute one of the major causes of
cell death in this transition (27). Moreover, activation of the
multifunctional Ca21-calmodulin protein kinase II (CaMKII),
which d-isoform is largely predominant in mammalian myo-
cardium (46), is a typical finding in heart failure from different
etiologies. Activation of this kinase also constitutes a main step
in the signaling cascade that leads to apoptosis following
several cardiac insults, like reperfusion injury (39), ionomycin,
high extracellular K1 concentration, intracellular acidosis, and
oxidative stress (28, 32, 47). Furthermore, intracellular reactive
oxygen species (ROS) levels increase dramatically in models
of structural heart disease (18), particularly those initiated by
ANG II (35). In recent in vitro experiments, our laboratory
described an apoptotic pathway that involves increases in ROS
produced by ANG II and activation of CaMKII (28). Exoge-
nous ANG II administration has also been linked to CaMKII
and apoptosis in vivo (11). Whether these events can also be
triggered by exacerbated endogenous ANG II production and
which is their impact, if any, on cardiac function, remains
unclear.
It has been shown that spontaneously hypertensive rats
(SHR), one of the most used models for hypertrophy and heart
failure studies, have high activity of the renin-angiotensin-
aldosterone system (RAAS) (45) and increased CaMKII ex-
pression (17). Hagemann et al. (17) described that CaMKIId is
overexpressed in hearts from adult SHR. Furthermore, normo-
tensive rats treated with high doses of isoproterenol (Iso), also
show high activity of RAAS (16). However, a possible asso-
ciation between endogenous levels of ANG II in different early
stage models of exacerbated RAAS activity and CaMKII-
induced apoptosis has not been previously studied. Moreover,
the functional consequences of RAAS exacerbation in early
stages of heart disease are an uncharted territory. Taking
advantage of these models, the present experiments were
undertaken to investigate the early repercussion of high RAAS
activity on CaMKII activation, apoptosis, and cardiac function.
METHODS
Animals and protocols. All procedures followed during this inves-
tigation conform to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH
Publication no. 85-23, revised 1996), and the experimental protocol
was approved by the Animal Welfare Committee of La Plata School
of Medicine.
Male SHR and normotensive aged-matched control Wistar rats were
used. At 3 mo, a group of SHR was treated with 10 mg·kg21·day21
enalapril, an inhibitor of the angiotensin converting enzyme (ACE), in the
drinking water for 1 mo.
Normotensive Wistar rats were treated at 3 mo with two subcuta-
neous injections of 250 mg/kg Iso, separated by a 24-h interval,
according to a previously described protocol (34), to induce cardiac
damage (3, 4, 30). Iso solution was prepared with sterile distilled acid
water, to prevent Iso oxidation, immediately before injection. Control
rats were injected with the solution without the drug. The rats treated
with Iso were further randomly assigned to receive enalapril (Ena)
(Iso-Ena rats) (at the doses and way mentioned for SHR) or no drug
(Iso-rats). An additional group of rats, receiving only Ena (Ena rats),
was used as control. All treatments were performed for 1 mo.
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Before and after the treatment, the animals were weighed, the
systolic blood pressure was measured by the tail-cuff method, and
echocardiographic examination was performed. Rats were then killed,
the heart was weighed, and the tibia length (TL) was measured. Hearts
were assigned for biochemical studies, immunohistochemical stain-
ing, ROS production determinations, or myocyte isolation for con-
tractile and intracellular Ca21 concentration ([Ca21]i) measurements.
Additionally, transgenic mice with cardiomyocyte-delimited trans-
genic expression of either a CaMKII inhibitory peptide (AC3-I) or a
scrambled control peptide (AC3-C) were used. Breeding mates of
these mice were generously supplied by Dr. Mark Anderson (Univer-
sity of Iowa) and reproduced and genotyped in our laboratory. The
mice were treated as the Iso-rats, i.e., animals were killed 1 mo after
injections, and the hearts were used for measuring ROS, CaMKII
activity, and apoptosis.
Aldosterone plasma levels. Aldosterone plasma levels were used as
an index of ANG II plasma levels (21) and RAAS activity. Blood
samples were centrifuged at 13,500 rpm for 15 min, and the plasma
was stored at 280°C until analysis. The plasma aldosterone concen-
tration was measured by standard radioimmunoassay method, accord-
ing to manufacturer instructions.
Echocardiographic examination. Echocardiogram was performed
in each rat under light anesthesia (35 mg/kg ip pentobarbital sodium).
Cardiac geometry and function were evaluated by two-dimensional
M-mode echocardiography with a 7-MHz linear transducer. All mea-
surements, including left ventricular (LV) wall thickness and diastolic
dimensions, were performed according to the American Society of
Echocardiography method (31). LV mass was calculated as previously
described (24).
Myocyte isolation. Rats were anesthetized by intra-abdominal in-
jection of pentobarbital sodium, and myocytes were isolated by
enzymatic digestion (29) and kept in a HEPES buffered solution at
room temperature (20–22°C), until used.
[Ca21]i and cell shortening. Isolated myocytes were loaded with
fura 2-AM (10 mmol/l for 15 min). [Ca21]i was measured with an
epifluorescence system (Ion Optix, Milton, MA). Briefly, dye-loaded
cells were placed in a chamber on the stage of an inverted microscope
(Nikon.TE 2000-U) and continuously superfused with a HEPES
Fig. 1. High renin-angiotensin-aldosterone system (RAAS) activity-induced hypertrophy in spontaneously hypertensive rats (SHR) is reversed by angiotensin
converting enzyme (ACE) inhibition. Aldosterone plasma levels, expressed as percentage of control values (A), systolic blood pressure values (B), and
hypertrophic parameters (C–G) are shown. C: heart weight-to-tibia length ratio (HW/TL). D and E: cross-sectional area (CSA) of the myocytes. F and G: left
ventricular mass. Representative echocardiographic images (F) and left ventricular mass normalized by tibia length [left ventricular mass index (LVMI); G] are
significantly increased in SHR. Enalapril (Ena) treatment prevents the increments in all of the parameters studied (A–G). Sp Th, septum thickness; Dd, diastolic
diameter; Pw Th, posterior wall thickness. Overall data are means 6 SE; n, no. of animals in each experimental group (in parentheses). *P , 0.05 vs. control.
§P , 0.05 1Ena vs. SHR.
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buffered solution at a constant flow of 1 ml/min at room temperature
(20–22°C). Myocytes were stimulated via two-platinum electrodes on
either side of the bath at 0.5 Hz. Fura 2 fluorescence was taken as an
index of the [Ca21]i. Resting cell length and cell shortening were
measured by a video-based motion detector (Ion Optix). Fluorescence
and cell shortening data were stored for off-line analysis (ION
WIZARD fluorescence analysis software).
ROS determinations: superoxide anion production. Cardiac tissue
slices from the LV (1–5 mm) were obtained and kept at 4°C until
assayed as previously described. Cardiac slices were kept in the assay
buffer during 30 min in a metabolic incubator before superoxide anion
(O2·2) production was measured by the lucigenin (5 mmol/l)-en-
hanced chemiluminescence method, after 20 min of incubation with
lucigenin, as previously described (8). The lucigenin-containing assay
buffer with tissue slices minus background was recorded. O2·2 pro-
duction was normalized to milligrams per dry weight per minute. The
increases in O2·2 production were expressed as differences from
control values.
Lipid peroxidation. Lipid peroxidation was determined by measur-
ing the rate of production of thiobarbituric acid reactive substances
(TBARS), expressed as nanomoles per milligram protein. Heart ho-
mogenates were centrifuged at 2,000 g for 10 min. Supernatants (0.5
ml) were mixed with 1.5 ml trichloroacetic acid (30% wt/vol) and 0.5
ml water, followed by boiling for 15 min. After cooling, absorbance
was determined spectrophotometrically at 535 nm, using a e value of
1.56 3 105 mmol·l·21·cm21 (5).
Western blot. Hearts were freeze-clamped and pulverized. Briefly,
0.1 g of tissue was homogenized in four volumes of lysis buffer (in
mmol/l, 30 KH2PO4, 25 NaF, 300 sucrose, 0.1 EDTA plus proteases
inhibitor cocktail). Protein was measured by the Bradford method
using BSA as standard. Lysates (;90 mg of total protein) were
separated per gel line in 10% SDS polyacrilamide gel (26) and
transferred to polyvinylidene difluoride membranes. Blots were
probed overnight with the following antibodies: Bcl-2 (Santa Cruz),
Bax (Santa Cruz), caspase-3 (Chemicon), phosphorylated CaMKII
(P-CaMKII) 1:1,000 (Abcam,), CaMKIId 1:1,000 (Santa Cruz),
Thr17-phosphorylated (P-Thr17) of phospholamban (PLN) 1:5,000
(Badrilla, Leeds, UK), PLN 1:5,000 (Badrilla, Leeds, UK). CaMKIId,
PLN, and GAPDH signals were used to normalize the signal intensity
of the different proteins, as it is mentioned in RESULTS. Immunoreac-
tivity was visualized by a peroxidase-based chemiluminescence de-
tection kit (Amersham Biosciences) using a Chemidoc Imaging sys-
tem. The signal intensity of the bands in the immunoblots was
quantified by densitometry, using Image J software (National Insti-
tutes of Health). Some proteins, i.e., Bcl-2, could appear as one or two
bands. It has been suggested that more than one band may correspond
to differentially phosphorylated forms or cleavage products (6, 23,
44). Due to this variation, we quantify the intensity of the two bands
together when they appear.
Apoptosis assays. Apoptosis was determined by terminal deoxynu-
cleotidyl transferase dUTP-mediated nick-end labeling (TUNEL) as-
say (In Situ Cell Death Detection Kit, TMR red, Roche, Mannheim,
Germany). The TUNEL-positive cells were imaged under a fluores-
cence microscope (3200 magnification) and counted in 10 random
fields for each experimental situation. The results were expressed as
percentage of TUNEL-positive cells related to total number of cells.
4=,6-Diamidino-2-phenylindole dihydrochloride (1 mg/ml, Sigma,
St. Lous, MO) was used for nuclear staining. Apoptotic cell death was
also assessed by immunoblotting, as described above, as the increase
in the ratio between the apoptotic signals Bax and the anti-apoptotic
signal Bcl-2 and the enhancement in the amount of the 17-kDa
cleavage product of caspase-3, indicating caspase-3 activation (28).
Exercise tolerance. Rats were pretested for their treadmill running
willingness at constant velocity of 15 m/min without slope, until
animals became exhausted or until they completed a 15-min period.
Statistics. All data are means 6 SE. Comparisons within groups
were made by either paired or unpaired Student’s t-test, as appropri-
Table 1. Echocardiographic parameters from control rats,
SHR, and SHR treated with enalapril
Control SHR SHR1Enalapril
n 9 8 6
LVDD, mm 5.59 6 0.32 6.44 6 0.16 6.07 6 0.11
STh, mm 1.52 6 0.03* 1.85 6 0.03* 1.71 6 0.02*
LVPWTh, mm 1.55 6 0.02* 1.92 6 0.06* 1.70 6 0.03*
ES, % 60.76 6 0.89 60.87 6 0.46 61.39 6 1.34
MVS, % 30.60 6 1.51 30.53 6 0.96 30.66 6 0.77
LVMI
mg/g 1.39 6 0.09* 2.61 6 0.12* 2.04 6 0.05*
mg/mm 12.79 6 1.05* 21.43 6 1.15* 17.81 6 0.39*
Values are means 6 SE; n, no. of rats. SHR, spontaneously hypertensive
rats; LVDD, left ventricular diastolic diameter; STh, septum thickness; LVP-
WTh, left ventricular posterior wall thickness; ES, endocardial shortening;
MVS, midwall ventricular shortening; LVMI, left ventricular mass index.
*P , 0.05 vs. all others groups.
Fig. 2. Ena blunts Ca21-calmodulin-dependent protein ki-
nase II (CaMKII) activity in SHR. A: typical blots of the
phosphorylated form of CaMKII (P-CaMKII) and of its
substrate, phospho-Thr17 residue of phospholamban (PLN;
P-Thr17) in control rats, SHR, and SHR treated with
Ena. Total CaMKIId and PLN expression are also
shown. SHR depicted an increment in both phosphor-
proteins, and the treatment with Ena prevented both
phosphorylations. B: average data of these experi-
ments. The signals of P-CaMKII and P-Thr17 were
normalized by their total respective proteins. These
experiments revealed that CaMKII is being activated
by ANG II. Values are means 6 SE; n, no. of animals
in each experimental group (in parentheses). *P , 0.05
vs. control. §P , 0.05, 1Ena vs. SHR.
2112 Apoptosis in Heart Via RAAS and CaMKII • Rueda JO et al.
J Appl Physiol • doi:10.1152/japplphysiol.01383.2011 • www.jappl.org
Downloaded from journals.physiology.org/journal/jappl (163.010.250.070) on September 29, 2020.
ate. One-way ANOVA was used for multigroup comparisons. The
Newman-Keuls test was used to examine statistical differences ob-
served with ANOVA. A value of P , 0.05 was taken to indicate
statistical significance.
RESULTS
High RAAS activity-induced cardiac hypertrophy and apop-
tosis in SHR is associated with CaMKII activation. Aldoste-
rone plasma levels and blood pressure were significantly in-
creased in 4-mo-old SHR with respect to age-matched normo-
tensive control rats (Fig. 1, A and B). Moreover, Fig. 1, C–G,
shows that SHR developed hypertrophy, as indicated by the
increase in the heart weight-to-TL ratio (HW/TL), the cross-
sectional area of the myocytes and the LV mass index (LVMI)
evaluated by echocardiography (see also Table 1). Represen-
tative images of echocardiography and LV specimens obtained
from each experimental group are shown in the right panels of
Fig. 1 (D and F). As shown in the examples of Fig. 1F and
Table 1, although hypertrophy is present in SHR (increase in
septum thickness, posterior wall thickness, and LVMI), no
Fig. 3. Cardiac apoptosis in SHR is prevented by
Ena. A: representative blots and average data of
the proapoptotic and antiapoptotic proteins Bax
and Bcl-2, respectively, and the 17-kDa cleavage
product of caspase-3 from control rats, SHR, and
SHR treated with Ena. GAPDH signals were
used as loading controls. The increased ratio
Bax/Bcl-2, used as an apoptotic index, and
caspase-3 activation in SHR, are prevented by
Ena treatment. B: typical photographs of terminal
deoxynucleotidyl transferase dUTP-mediated
nick-end labeling (TUNEL) assay and 4=,6-di-
amidino-2-phenylindole dihydrochloride (DAPI)
staining of control, SHR, and SHR treated with
Ena. The mean values of TUNEL-positive cells
normalized by total DAPI-stained nuclei in the
bar graph below indicate that the increment in
apoptosis in SHR is prevented by blocking
RAAS axis. Values are means 6 SE; n, no. of
animals in each experimental group (in parenthe-
ses). *P , 0.05 vs. control. §P , 0.05, 1Ena vs.
SHR.
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signs of pump failure were detected, i.e., there were no signif-
icant changes in LV diastolic diameter and endocardial and
midwall shortening (Table 1). Similarly, the ergometric test
was similar between SHR and control rats, i.e., rats stopped
running after 8.37 6 0.82 vs. 8.25 6 0.88 min, respectively.
Ena treatment of SHR prevented the increase in aldosterone
plasma levels, indicating the inhibition of RAAS, and slightly
but significantly decreased blood pressure (Fig. 1, A and B).
Moreover, the increase in hypertrophic parameters (HW/TL,
cross-sectional area, and LVMI) was also prevented by ACE
inhibition (Fig. 1, C–G, and Table 1).
Figure 2 shows typical blots and average results of P-
CaMKII and total CaMKIId, and one of its typical substrates,
P-Thr17 of PLN, and total PLN. There was a significant
increment in CaMKII and Thr17 phosphorylation in SHR,
indicative of CaMKII activation, that was prevented by Ena
treatment.
Typical blots and average data of the proapoptotic and
antiapoptotic proteins Bax and Bcl-2, respectively, the 17-kDa
cleavage product of caspase-3 and TUNEL staining (Fig. 3, A
and B, respectively) indicated a significantly higher degree of
apoptosis in SHR than in age-matched controls that was pre-
vented by ACE inhibition.
The increase in RAAS produced by Iso treatment induces
apoptosis and CaMKII activation in rat hearts. We also inves-
tigated whether CaMKII was implicated in inducing apoptosis
in another high RAAS activity model produced after 1 mo of
Iso treatment (4, 16, 30).
As in the case of SHR, high doses of Iso induced an increase
in aldosterone plasma levels, blood pressure, and hypertrophy
(increased HW/TL relationship and LVMI) (Fig. 4, A and B)
without significant signs of heart failure in the echocargraphic
recordings (endocardial and midwall ventricular shortening
remains unaltered, Table 2). Moreover, the ergometric test was
not different between Iso-rats and their controls (8.50 6 0.93
vs. 8.37 6 0.82 min). Treatment of the animals with Ena
significantly decreased the aldosterone plasma levels, indicat-
ing blockade of the RAAS. Although blood pressure tended to
decrease in the Ena-treated group, this decrease did not reach
significance. In turn, hypertrophy present in the Iso-rats was
prevented by ACE inhibition (Fig. 4, A and B, and Table 2).
Consistent with the results obtained in SHR, Fig. 4, C and D,
shows that apoptosis (increased TUNEL-positive cells, Bax/
Bcl-2 ratio, and caspase-3 activation) and the increased CaMKII
activity induced by Iso treatment (CaMKII and Thr17 site of
PLN phosphorylations) were prevented by ACE inhibition with
Ena.
Taken together, these results indicate that the enhancement
of RAAS in SHR and Iso-rats is associated with a significant
increase in CaMKII activity and apoptosis, suggesting a pos-
sible causal link between both events in vivo. It is worth noting
that, despite the structural remodeling and apoptosis observed,
heart function remains preserved in these rats.
CaMKII activity in high RAAS activity models is associated
with ROS production and not with [Ca21]i increases. CaMKII
activation is conventionally associated with [Ca21]i incre-
ments. Moreover, recent experiments have emphasized the
importance of ROS in the activation of the kinase [see for
review, Erikson et al. (10)]. We, therefore, explored [Ca21]i
handling and ROS production in an attempt to elucidate the
source of CaMKII activation in our models.
We first assessed [Ca21]i handling in isolated myoytes from
both high RAAS activity models. Figure 5A shows typical
superimposed records of cellular shortening and [Ca21]i tran-
sients (CaiT) of the SHR (red traces) and their normotensive
controls (black traces). The average results (Fig. 5B) show that
no differences were detected between both groups in contrac-
tion amplitude, CaiT, and sarcoplasmic reticulum Ca21 con-
tent, assessed by the amplitude of the caffeine-induced CaiT.
Moreover, diastolic and systolic Ca21 did not reach significant
difference between SHR and their controls. Mean values were
1.124 6 0.035 and 1.571 6 0.059 for control vs. 1.053 6
0.031 and 1.556 6 0.060 for SHR, for diastolic and systolic
Fura 2-AM fluorescence, respectively. Similar results were
Fig. 4. Ena treatment prevents isoproterenol (Iso)-induced hypertrophy, CaMKII activation, and apoptosis. A: from left to right, aldosterone plasma levels, blood
pressure, and the hypertrophic indexes, HW/TL and the LVMI, measured by echocardiography, from control rats, Iso, and Iso1Ena treated rats. All of the
parameters show an increment in Iso-rats that is prevented by the cotreatment with Ena. B: representative echocardiographic images of the groups examined in
A. C: TUNEL and DAPI photographs of the different groups and mean values of these experiments, indicating an increment in TUNEL-positive cells normalized
by total DAPI-stained nuclei, only in Iso-rats. D: typical blots and average data of P-CaMKII and its substrate, P-Thr17 of PLN; of apoptotic and anti-apoptotic
proteins, Bax and Bcl-2, respectively; and of active caspase-3 from control, Iso, and Iso1Ena groups. Total CaMKIId, PLN, and GAPDH are also shown. Iso
treatment induces an increase in CaMKII activity (P-CaMKII and P-Thr17), in the apoptotic index (Bax-to-Bcl-2 ratio) and in caspase-3 activation, which are
prevented by Ena treatment. These groups of experiments link the increase in RAAS activity with apoptosis and CaMKII activation. AU, arbitrary units. Values
are means 6 SE; n, no. of animals in each experimental group (in parentheses). *P , 0.05 vs. control. ¤P , 0.05, 1Ena vs. Iso.
Table 2. Echocardiographic parameters from control rats, isoproterenol rats, and isoproterenol rats treated with enalapril
Wistar Wistar Isoproterenol Wistar1Enalapril Wistar Isoproterenol1Enalapril
n 12 29 4 7
LVDD, mm 5.20 6 0.13* 5.81 6 0.07* 3.72 6 0.12* 4.43 6 0.23*
STh, mm 1.54 6 0.03‡ 1.64 6 0.02† 1.26 6 0.02†‡ 1.23 6 0.05†‡
LVPWTh, mm 1.56 6 0.02‡ 1.70 6 0.02† 1.24 6 0.02†‡ 1.22 6 0.04†‡
ES, % 60.76 6 0.70 59.86 6 0.40 58.98 6 1.0 58.52 6 0.86
MVS, % 30.16 6 1.32 33.03 6 0.90 33.1 6 1.02 34.52 6 0.91
LVMI
mg/g 1.38 6 0.08 1.91 6 0.04† 1.70 6 0.04† 1.71 6 0.04†‡
mg/mm 11.18 6 0.47‡ 14.28 6 0.36† 5.16 6 0.06†‡ 6.76 6 0.91†‡
Values are means 6 SE; n, no. of rats. *P , 0.05 vs. all others groups. †P , 0.05 vs. Wistar rats. ‡P , 0.05 vs. Wistar isoproterenol rats.
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obtained when Iso-rats were compared with their controls. As
shown in Fig. 5C, there were no differences between Iso and
control rats in the contraction amplitude, CaiT amplitude, or
in the sarcoplasmic reticulum Ca21 content, suggesting that
global Ca21 levels underlying each contractile cycle do not
differ between the two groups. These results are in agreement
with the absence of signs of cardiac dysfunction (Tables 1 and
2 and the ergometric test). The absence of difference in Ca21
handling confirms in in vivo models our previous in vitro and
ex vivo findings, where CaMKII was activated by ANG II in
the absence of detectable increases in [Ca21]i (28).
In a second set of experiments, we estimated oxidative stress
by measuring O2·2 production and lipid peroxidation in SHR,
Iso-rats, and their controls. Figure 6A shows the increment in
O2·2 generation measured by using lucigenin chemilumines-
cence in SHR and Iso-rats with respect to control rats. Accord-
ingly, TBARS, used to determine lipid peroxidation, also
increased in SHR and Iso-rats compared with their controls
(Fig. 6B). Taken together, these results indicated that the
increase in CaMKII activity in these two models of exacer-
bated RAAS cannot be associated with an enhanced [Ca21]i
and occurs together with an increase in ROS production.
Targeted cardiac inhibition of CaMKII prevents apoptosis
but does not inhibit ROS production in Iso-treated mice. To
verify a possible causal link between ROS production, CaMKII
activation, and apoptosis, we used mice with cardiomyocyte-
delimited transgenic expression of either a CaMKII inhibitory
peptide (AC3-I) or a scrambled control peptide (AC3-C), after
1 mo of Iso treatment. As shown in Fig. 7, Iso treatment
increased TBARS, an index of lipid peroxidation, in both
AC3-C and AC3-I mice (A), indicating an increase in oxidative
stress. However, CaMKII activity, measured by the increase in
P-CaMKII and in the phosphorylation of Thr17 site of PLN
(Fig. 7, B), and apoptosis, assessed by the increase in TUNEL
staining (C) and the ratio Bax/Bcl2 (D), only increased in
AC3-C mice. Similarly, caspase-3 activation was increased in
AC3-C mice treated with Iso by 279 6 73.5% above control,
whereas it did not change significantly in Iso-treated AC3-I
mice.
These latter results indicate that the increase in ROS that
occurred after Iso treatment is upstream of CaMKII activation,
and that the kinase activity is directly related to the induction
of apoptosis.
DISCUSSION
ANG II has been shown to be implicated in many cellular
physiological and pathological processes. In the long term, the
hormone has been associated with cardiomyocyte apoptosis
(27, 33, 40). Moreover, experimental evidence indicates that a
critical factor in the transition from compensated to noncom-
pensated cardiac hypertrophy is myocyte cell loss by apoptosis
(1), and that the circulating levels of ANG II are increased in
heart failure. It has, therefore, been proposed that increased
ANG II levels may constitute one of the major triggers for cell
death in the transition to heart failure (20). Interestingly, the
onset of ANG II plasma or tissue increment during the devel-
opment of cardiac diseases may start well ahead of the detec-
Fig. 5. Unaltered Ca21 handling in control rats,
SHR, and Iso-treated rats. A: representative su-
perimposed recording of cell length and intracel-
lular Ca21 concentration transients (CaiT) from
isolated myocytes of control rats (black trace)
and SHR (red trace). The contraction amplitude
and the CaiT amplitude under field-stimulated
conditions (0.5 Hz) or under caffeine pulse (25
mmol/l) were not different between the strains.
DFFI, change in Fura 2 fluorescence intensity.
B: average data of these experiments. C: mean
values of these parameters comparing control
with Iso-rats. There were no significant differ-
ences in any of the variables studied between
SHR or Iso-rats with respect to their controls.
Values are means 6 SE; n, no. of myocytes in
each experimental group (in parentheses).
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tion of cardiac damage. Moreover, tissue concentrations of
ANG II are difficult to establish, and they may reach very high
levels (over 100 times plasma concentrations) (7) during car-
diac remodeling. Thus, to establish the pathophysiological
relevance of ANG II using in vitro experimental tools or
animals models where ANG II is exogenously administrated is
not straightforward and requires in vivo validation. To the best
of our knowledge, the in vivo effects of enhanced RAAS at an
early stage during the development of heart disease have not
been previously studied.
In the present study, we used two different models of heart
disease with exacerbated RAAS well before the appearance of
signs or symptoms of heart failure. The main conclusions of
our results are the following: 1) exacerbation of RAAS in these
models is an early event necessary to activate CaMKII and to
induce cardiac apoptosis; 2) CaMKII activation and cardiomyo-
cyte loss are early signs in the maladaptive processes impli-
cated in the transition from compensated to decompensated
LV hypertrophy (13, 22); 3) activation of CaMKII occurs in
vivo without detectable [Ca21]i increments and is directly
related to the increase in ROS and the induction of apopto-
sis. These results support the contention that ANG II-
induced oxidative stress resets the Ca21 dependence of
CaMKII, as observed in our laboratory’s previous in vitro
and ex vivo experiments (28).
Animal models. The models used are widely known as
cardiac hypertrophy and failure models.
The SHR model is paradigmatic, since it mimics human
essential hypertension, and several reports described that en-
docrine and paracrine RAAS are active (38, 45). Although a
variety of factors modify aldosterone secretion, ANG II and
potassium (43) are the most important regulators. Thus the
increased aldosterone plasma levels found in our animals can
be taken as an index of ANG II levels, as previously described
(2, 45).
The Iso-induced cardiac injury model is recognized as one of
the toxic cardiomyopathy models of hypertrophy and heart
failure (9, 16, 34). Excessive doses of catecholamines produce
diffuse myocardial destruction with myocyte loss and necrosis,
as well as extensive fibrosis in animals and in patients. This
kind of damage may also be seen in patients with pheochro-
mocytoma (37). In this model, an exacerbation of RAAS was
previously described (16) and confirmed by the present results.
In the present work, we used these two models of enhanced
RAAS at an early stage of disease, as evident by the significant
degree of hypertrophy without heart failure signs.
The early signs of heart disease. Typically, heart failure is
the culmination of long-standing diseases, such as hyperten-
sion, ischemia from atherosclerosis, viral myocarditis, valvular
insufficiency, or mutations in genes encoding sarcomeric pro-
teins (2, 25). Besides contractile disturbances of cardiomyo-
cytes and interstitial and perivascular fibrosis, cardiomyocyte
loss is now being considered as one of the determinant factors
of the maladaptive events that negatively impacts the myocar-
dium and its propensity toward failure (12). Although the
apoptotic rate observed in the present results is low, rodent
studies have implicated low rates of cardiac myocyte apoptosis
in the pathogenesis of heart failure. For instance, it has been
previously shown that an apoptotic rate as low as 0.023% is
sufficient to cause a lethal, dilated cardiomyopathy within
8–24 wk in transgenic mice with cardiac-restricted expression
of an inducible caspase-8 allele (41). There is no information
concerning the magnitude of cell loss required to depress
cardiac contractility in the hypertrophied human heart when
cell death occurs (15). Indeed, the apoptotic process takes at
most 24 h to be completed, and heart failure is a condition that
only manifests itself after many years. Thus it is conceivable
that chronic loss of small number of cardiomyocytes on a daily
Fig. 6. Superoxide anion (O2·2) and lipid peroxidation are increased in SHR
and Iso-rats. A: O2·2 generation by myocardial slices from control (•), Iso (‘),
and SHR (X). Both Iso and SHR display a significant increase in O2·2
production. The data fitted with a one-phase exponential association (Graph-
Pad Prism 4.2) from SHR and Iso-rats were significantly higher than the
control curve. For better comparison, the bar graph below depicts the mean
values at 20 min, when the reaction was completely stabilized, showing a
significant increment in O2·2 generation in Iso and SHR with respect to control
rats. AU, arbitrary units; CPM, counts/min. B: average data of thiobarbituric
acid reactive substances (TBARS), indicating that SHR and Iso-rats present
higher levels of lipid peroxidation than control rats. Values are means 6
SE; n, no. of animals in each experimental group (in parentheses). *P ,
0.05 vs. control.
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basis can have dramatic consequences on myocardial integrity
(36). Moreover, myocardial apoptosis is evident in the myo-
cardium before the occurrence of ventricular dilation and the
development of symptoms, which suggests that apoptosis is a
causative mechanism rather than a consequence of failure (14).
The present results reveal that the increase in apoptotic death,
as well as the enhanced activity of CaMKII, are early events in
these and probably other models with exacerbated RAAS.
Since apoptosis paralleled hypertrophy in these two models,
the results may indicate that apoptosis represents either an
early step in the evolution to heart failure being involved in
cardiac remodeling or a mechanism tending to compensate the
development of hypertrophy. Further studies are currently on
course to discriminate between these possibilities.
Ca21 vs. ROS and the role of CaMKII in cardiac disease.
CaMKII is typically activated by increments in [Ca21]i and
calmodulin (Ca21/Cam). The complex Ca21/Cam promotes
a conformational change that relieves the autoinhibitory
effect of the regulatory domain on the kinase, activating the
enzyme. In the sustained presence of Ca21/Cam, CaMKII
undergoes intersubunit autophosphorylation, resulting in
Ca21/Cam-independent activity. Recent experimental evidence
indicated that ROS-induced oxidation of methionine residues is
able to sustain CaMKII activity in the absence of Ca21/CaM.
This action requires, however, previous binding of Ca21/Cam
to expose the autoinhibitory domain of CaMKII for oxidation
(11). Interestingly, in a previous study, our laboratory con-
cluded that ROS resets the dependence of CaMKII to Ca21 to
extremely low [Ca21]i levels (28). The present results obtained
in two different in vivo models are consistent with these
previous findings, since the increased activity of CaMKII
occurred in the absence of any detectable increase in [Ca21]i,
but in the presence of a significant increase in ROS production.
Our results in transgenic mice further indicate that ROS pro-
duction is upstream of CaMKII activation in the cascade of
events that produces apoptosis after Iso treatment. In this
Fig. 7. Mice with cardiomyocyte-delimited transgenic expression of CaMKII inhibitory peptide are protected from Iso-induced apoptosis. A: lipid peroxidation
measured by TBARS indicates that Iso treatment increases oxidative stress in both AC3-C and AC3-I mice. B: representative blots from P-CaMKII and P-Thr17,
and their respective total proteins, as an index of CaMKII activity, and average results, show that, under Iso treatment, only AC3-C mice increase phosphorylation
of CaMKII and PLN at the CaMKII site. C: TUNEL and DAPI photographs of the different groups and mean (SE) values of these experiments, indicating a
significant increment in TUNEL-positive cells normalized by total DAPI stained nuclei only in the AC3-C mice treated with Iso (***). D: typical blots of pro-
and anti-apoptotic protein Bax, and Bcl-2, and mean (6SE) results in the bar graph below. GAPDH signals were used as loading controls. Iso treatment induced
apoptosis only in AC3-C mice. *P , 0.05 vs. other groups. ***P , 0.001 vs. other groups.
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context, it is worthwhile to mention that ROS-induced phos-
phatase inhibition could also contribute to sustained CaMKII
activation in vivo (19).
Perspectives. The present results clearly indicate that acti-
vation of CaMKII and the associated apoptosis are very early
events in the development of heart disease that are evident even
when the only manifestation of the injury is the presence of
hypertrophy, without any sign or symptom of cardiac dysfunc-
tion. They further show that CaMKII activity and apoptosis can
both be prevented by inhibition of RAAS. Whether the data
can be extrapolated to humans remains to be shown. However,
the apoptotic rate obtained in the present results is much lower
than the one measured in cardiac tissue from patients with
end-stage heart failure, suggesting that apoptosis may also be a
causal mechanism of human heart failure. If so, cardiac myo-
cyte apoptosis and CaMKII may constitute novel targets for
therapies directed against heart failure. Moreover, in the con-
text of hypertrophy and hypertension, activation of CaMKII
could be considered an early index of bad prognosis.
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